A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy.
PCNSL
natalizumab
primary central nervous system lymphoma
natalizumab